- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.12. | H.C. Wainwright hebt Kursziel für Maze Therapeutics auf 60 US-Dollar an | 1 | Investing.com Deutsch | ||
| 04.12. | Maze Therapeutics stock rating initiated at Overweight by Wells Fargo | 4 | Investing.com | ||
| 13.11. | Raymond James startet Coverage für Maze Therapeutics mit "Outperform" | 7 | Investing.com Deutsch | ||
| 13.11. | Raymond James initiates Maze Therapeutics stock with Outperform rating | 3 | Investing.com | ||
| 06.11. | Maze Therapeutics, Inc.: Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights | 91 | GlobeNewswire (Europe) | First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected... ► Artikel lesen | |
| 06.11. | Maze Therapeutics to present data on kidney disease therapies at ASN meeting | 9 | Investing.com | ||
| 17.10. | Maze Therapeutics files to sell 9.23M shares of common stock for holders | 2 | Seeking Alpha | ||
| 17.10. | Maze Therapeutics, Inc. - S-1, General form for registration of securities | 2 | SEC Filings | ||
| MAZE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 06.10. | Maze Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 06.10. | Maze Therapeutics appoints Hervé Hoppenot as board chairman | 10 | Investing.com | ||
| 06.10. | Maze Therapeutics, Inc.: Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors | 169 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for... ► Artikel lesen | |
| 03.10. | Maze Therapeutics stock rating reiterated at Buy by H.C. Wainwright | 1 | Investing.com | ||
| 03.10. | Maze Therapeutics: H.C. Wainwright bestätigt "Buy"-Rating und sieht deutliches Aufwärtspotenzial | 4 | Investing.com Deutsch | ||
| 19.09. | Maze Therapeutics, Inc. (MAZE): A Bull Case Theory | 18 | Insider Monkey | ||
| 15.09. | Maze Therapeutics stock price target raised to $34 at Guggenheim on promising PKU data | 3 | Investing.com | ||
| 15.09. | Maze Therapeutics: Guggenheim erhöht Kursziel nach vielversprechenden PKU-Studiendaten deutlich auf 34 $ | 1 | Investing.com Deutsch | ||
| 14.09. | Maze Therapeutics Drug Shows Potential to Top Asset Acquired by Otsuka for $800M | 4 | MedCity News | ||
| 12.09. | Doppeltes Potenzial treibt Aktie an: H.C. Wainwright hebt Kursziel für Maze Therapeutics deutlich an | 2 | Investing.com Deutsch | ||
| 12.09. | Maze Therapeutics stock jumps as H.C. Wainwright raises price target on dual potential | 1 | Investing.com | ||
| 11.09. | Maze Therapeutics stock price target raised to $37 at BTIG on strong data | 1 | Investing.com |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABIVAX | 107,40 | +0,19 % | Abivax vor möglicher Übernahme: NBC-Volltreffer liefert +200% Kursgewinn | Nachdem sich die Aktie der französischen Biotechschmiede Abivax in den letzten Monaten schon vervielfachen konnte, verzeichnet sie am heutigen Mittwoch noch einmal einen kräftigen Kurssprung von zeitweise... ► Artikel lesen | |
| CYTOKINETICS | 52,00 | -3,70 % | Cytokinetics, Incorporated: Cytokinetics Announces Positive CHMP Opinion of MYQORZO (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy | Final Decision from European Commission Expected in Q1 2026 SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Committee... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 8,205 | -3,64 % | Ventyx Biosciences, Inc.: Ventyx Provides Clinical and Corporate Updates | Strengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby, MD as a Clinical AdvisorExpanding the Phase 2 recurrent pericarditis study into Canada, EU and... ► Artikel lesen | |
| NURIX THERAPEUTICS | 19,070 | 0,00 % | Cathie Wood's ARK sells Iridium stock, buys Nurix on Wednesday | ||
| REZOLUTE | 1,520 | -1,30 % | Rezolute, Inc.: Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism | Study did not meet the primary or key secondary endpoint 45% reduction in hypoglycemia events observed at top ersodetug dose (10 mg/kg) compared to 40% improvement in placebo arm Management to host... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 77,08 | +0,72 % | Apogee Therapeutics stock initiated with Buy rating at Deutsche Bank | ||
| TREVI THERAPEUTICS | 12,775 | -3,07 % | Trevi Therapeutics, Inc. - 8-K, Current Report | ||
| CELCUITY | 92,00 | +2,22 % | Gedatolisib: Vielversprechende Studiendaten zu Brustkrebsmedikament beflügeln Celcuity-Aktie | ||
| PEPGEN | 5,670 | -1,39 % | PepGen appoints Joseph Vittiglio as chief business and legal officer | ||
| STRUCTURE THERAPEUTICS | 67,06 | -0,56 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs | SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| COGENT BIOSCIENCES | 42,110 | +5,17 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 40,510 | +2,30 % | Harmony Biosciences Holdings, Inc.: Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress | Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will present data from its rare epilepsy pipeline at the 36th International Epilepsy Congress (IEC) being held August 30... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 71,83 | +0,32 % | Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity | ||
| LENZ THERAPEUTICS | 18,140 | -25,96 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ) in South Korea for the Treatment of Presbyopia | SAN DIEGO and TAIPEI, Taiwan, Dec. 01, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced that Lotus... ► Artikel lesen | |
| QIAGEN | 38,345 | -0,67 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen |
Das Unternehmen MAZE THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,77 % bei einem Aktienkurs von 38,860 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAZE THERAPEUTICS INC finden Sie auf Wallstreet Online.